Recently, Bosheng Jianke Cell Technology Co., Ltd., a shareholding company of Anke Biotech, announced that the key phase II clinical trial of its self-developed innovative drug PA3-17 injection has successfully completed the first patient administration in the country at the First Affiliated Hospital of Zhengzhou University. This key development marks that this breakthrough treatment for T-cell malignancies has officially entered the core stage of clinical value verification.

Recently, Bosheng Jianke Cell Technology Co., Ltd., a shareholding company of Anke Biotech, announced that the key phase II clinical trial of its self-developed innovative drug PA3-17 injection has successfully completed the first patient administration in the country at the First Affiliated Hospital of Zhengzhou University. This key development marks that this breakthrough treatment for T-cell malignancies has officially entered the core stage of clinical value verification.